-+ 0.00%
-+ 0.00%
-+ 0.00%

SoftOx doses first patient in Phase 2a SIS-03 trial for chronic airway infections

PUBT·08/11/2026 08:37:16
Listen to the news
SoftOx doses first patient in Phase 2a SIS-03 trial for chronic airway infections
  • SoftOx Solutions on Aug. 11, 2026 dosed the first patient in the Phase 2a SIS-03 proof-of-concept trial for chronic airway infections.
  • Results have not been presented; the patient phase is expected to conclude in H1 2027.
  • The study aims to show early clinical and microbiological activity, including signs of reduced bacterial burden, building on a prior safety review in healthy volunteers.
  • The company guided to enroll 15-25 patients in collaboration with Rigshospitalet in Copenhagen.
  • SoftOx highlighted a commercial opportunity of more than USD 600 million in cystic fibrosis inhaled antibiotics, with a larger potential market above USD 5 billion in non-CF bronchiectasis.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SoftOx Solutions AS published the original content used to generate this news brief on August 11, 2026, and is solely responsible for the information contained therein.